Exonics Therapeutics
Boston
About Exonics Therapeutics
Exonics’ laboratory has demonstrated the ability to use adeno-associated virus (AAV) to deliver a payload based on CRISPR/Cas9 technology that can identify and correct exon mutations that prevent the production of dystrophin, a protein that helps stabilize and protect muscle fibers.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $45.0M
- Funding stage: M&A
- Last round: Series A (Nov 2017)
- Website: exonicstx.com
- Phone: (857)288-1518
Industries & Categories
Biopharma, Biotechnology, Medical Device, Therapeutics
Canonical: https://fsome.com/organization/exonics-therapeutics-49706 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.